首站-论文投稿智能助手
典型文献
Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma
文献摘要:
Pancreatic ductal adenocarcinoma (PDAC) is a common cause of cancer-related death, and most patients are with advanced disease when diagnosed. At present, despite a variety of treatments have been devel- oped for PDAC, few effective treatment options are available; on the other hand, PDAC shows significant resistance to chemoradiotherapy, targeted therapy, and immunotherapy due to its heterogeneous genetic profile, molecular signaling pathways, and complex tumor immune microenvironment. Nevertheless, over the past decades, there have been many new advances in the key theory and understanding of the in- trinsic mechanisms and complexity of molecular biology and molecular immunology in pancreatic can- cer, based on which more and more diverse new means and reasonable combination strategies for PDAC treatment have been developed and preliminary breakthroughs have been made. With the continuous ex- ploration, from surgical local treatment to comprehensive medical management, the research-diagnosis- management system of pancreatic cancer is improving. This review focused on the variety of treatments for advanced PDAC, including traditional chemotherapy, targeted therapy, immunotherapy, microenviron- ment matrix regulation as well as the treatment targeting epigenetics, metabolism and cancer stem cells. We pointed out the current research bottlenecks and future exploration directions.
文献关键词:
作者姓名:
Ri-Lan Bai;Nan-Ya Wang;Ling-Ling Zhao;Yong-Fei Zhang;Jiu-Wei Cui
作者机构:
Cancer Center,the First Hospital of Jilin University,Changchun 130021,China
引用格式:
[1]Ri-Lan Bai;Nan-Ya Wang;Ling-Ling Zhao;Yong-Fei Zhang;Jiu-Wei Cui-.Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma)[J].国际肝胆胰疾病杂志(英文版),2022(01):10-24
A类:
ploration
B类:
Diverse,precision,therapies,open,new,horizons,patients,advanced,pancreatic,ductal,adenocarcinoma,Pancreatic,PDAC,common,cause,cancer,related,death,most,are,disease,when,diagnosed,At,present,despite,variety,treatments,have,been,few,effective,options,available,hand,shows,significant,resistance,chemoradiotherapy,targeted,immunotherapy,due,its,heterogeneous,profile,molecular,signaling,pathways,tumor,immune,microenvironment,Nevertheless,over,past,decades,there,many,advances,key,theory,understanding,trinsic,mechanisms,complexity,biology,immunology,which,more,diverse,means,reasonable,combination,strategies,developed,preliminary,breakthroughs,made,With,continuous,from,surgical,local,comprehensive,medical,management,research,diagnosis,system,improving,This,review,focused,including,traditional,chemotherapy,matrix,regulation,well,targeting,epigenetics,metabolism,cells,We,pointed,out,current,bottlenecks,future,exploration,directions
AB值:
0.599625
相似文献
Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+T cell-mediated ferroptosis in castration-resistant prostate cancer
Xumin Zhou;Libin Zou;Hangyu Liao;Junqi Luo;Taowei Yang;Jun Wu;Wenbin Chen;Kaihui Wu;Shengren Cen;Daojun Lv;Fangpeng Shu;Yu Yang;Chun Li;Bingkun Li;Xiangming Mao-Department of Urology,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China;Second Department of Hepatobiliary Surgery,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China;Department of Urology,Minimally Invasive Surgery Center,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China;Department of Urology,Guangzhou Women and Children's Medical Center,Guangzhou Medical University,Guangzhou 510623,China;Department of Urology,Peking University Shenzhen Hospital,Shenzhen 518036,China;Nursing Department,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China
Therapeutic potential of traditional Chinese medicine for the treatment of NAFLD:A promising drug Potentilla discolor Bunge
Longshan Ji;Qian Li;Yong He;Xin Zhang;Zhenhua Zhou;Yating Gao;Miao Fang;Zhuo Yu;Robim M.Rodrigues;Yueqiu Gao;Man Li-Laboratory of Cellular Immunity,Institute of Clinical Immunology,Shanghai Key Laboratory of Traditional Chinese Medicine,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Key Laboratory of Liver and Kidney Diseases(Shanghai University of Traditional Chinese Medicine),Ministry of Education,Shanghai 201203,China;Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;Department of Hepatopathy,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Department of in Vitro Toxicology and Dermato-Cosmetology,Faculty of Medicine and Pharmacy,Vrije Universiteit Brussel,Brussels 1000,Belgium
Bone metastasis of hepatocellular carcinoma:facts and hopes from clinical and translational perspectives
Zhao Huang;Jingyuan Wen;Yufei Wang;Shenqi Han;Zhen Li;Xuemei Hu;Dongling Zhu;Zhenxiong Wang;Junnan Liang;Huifang Liang;Xiao-ping Chen;Bixiang Zhang-Hepatic Surgery Center,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;Clinical Medical Research Center of Hepatic Surgery at Hubei Province,Wuhan 430030,China;Hubei Key Laboratory of Hepato-Pancreatic-Biliary Diseases,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;Department of Radiology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;Department of Nuclear Medicine and PET Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;Department of Radiology,Guangzhou First People's Hospital,School of Medicine,South China University of Technology,Guangzhou 510180,China;Key Laboratory of Organ Transplantation,Ministry of Education;Key Laboratory of Organ Transplantation,National Health Commission;Key Laboratory of Organ Transplantation,Chinese Academy of Medical Sciences,Wuhan 430030,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。